monoclonal antibodies

March 25, 2019

VUMC joins effort to stop spread of two deadly viruses

Researchers at Vanderbilt University Medical Center are participating in a national effort to develop vaccines and other treatments as countermeasures to prevent the spread of two emerging and deadly viruses — Nipah and Hendra.

By Bill Snyder
February 21, 2019

VUMC chikungunya antibody set to enter clinical trial

A monoclonal antibody against the chikungunya virus developed by researchers at Vanderbilt University Medical Center is the first monoclonal antibody encoded by messenger RNA to enter a clinical trial.

By Bill Snyder
Research assistant Mahsa Majedi loads reagent used in DNA sample preparation in the genomics lab. She is part of a team of more than a dozen people at VUMC who are “sprinting” to develop — within 90 days — an antibody-based treatment to stop the spread of the Zika virus.
January 24, 2019

VUMC scientists ‘sprint’ to find anti-Zika antibodies

Scientists at Vanderbilt University Medical Center and colleagues in Boston, Seattle and St. Louis are racing to develop — in a mere 90 days — a protective antibody-based treatment that can stop the spread of the Zika virus.

By Bill Snyder
December 6, 2018

Discovery could lead to neutralizing West Nile virus

Researchers at Vanderbilt University Medical Center and colleagues have isolated a human monoclonal antibody that can “neutralize” the West Nile virus and potentially prevent a leading cause of viral encephalitis (brain inflammation) in the United States.

By Bill Snyder
August 30, 2018

Team isolates antibodies that neutralize GI bug norovirus

Researchers at Vanderbilt University Medical Center have isolated the first human monoclonal antibodies that can neutralize norovirus, the leading cause of acute gastrointestinal illness in the world.

By Bill Snyder
July 19, 2018

Team finds potent antibodies against three Ebola viruses

Researchers at Vanderbilt University Medical Center and their colleagues are a step closer to developing a broadly effective antibody treatment against the three major Ebola viruses that cause lethal disease in humans.

By Bill Snyder
May 17, 2018

Alphavirus “Achilles heel”

Targeting the protein that mosquito-borne viruses use to enter cells could be a strategy for preventing infection by multiple emerging viruses.
By Bill Snyder
April 26, 2018

Study seeking to isolate antibodies against rabies virus

Few people die from rabid animal bites in the United States thanks to the near-universal availability of human rabies immune globulin and rabies vaccine, which are given as separate shots as soon as possible after exposure to the rabies virus.
By Bill Snyder
February 23, 2018

Hope for an RSV vaccine

Newly discovered features in an RSV protein may be useful for rational structure-based vaccine design.
By Bill Snyder
October 17, 2017

Researchers find novel mechanism of resistance to anti-cancer drugs

Vanderbilt investigators have discovered a novel non-genetic cause of resistance to the targeted anti-cancer therapy cetuximab. Their findings, reported this week in Nature Medicine, suggest a strategy for overcoming this resistance.
By Leigh MacMillan
October 12, 2017

Researcher targets peanut allergies with Cohen Fund support

Scott Smith, M.D., Ph.D., assistant professor of Medicine, has received a 2017 research award from the Stanley Cohen Innovation Fund to test a new therapeutic strategy for peanut allergies. Smith's research could fundamentally change allergy treatment.
By Leigh MacMillan
February 9, 2017

Team isolates new antibodies that may aid RSV vaccine design

Researchers at Vanderbilt University Medical Center (VUMC) have taken another step toward developing a vaccine against respiratory syncytial virus (RSV), the major cause of life-threatening pneumonia in infants worldwide.
By Bill Snyder
October 20, 2016

Preparing for a return of pox

To prepare for the potential of a smallpox return, Vanderbilt researchers are isolating and studying naturally occurring antibodies from the blood of previously infected or immunized people.
By Bill Snyder